GT
XBIT icon

Glenmede Trust’s XBiotech XBIT Stock Holding History

Glenmede Trust’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-46
Closed – – 2285
2020
Q3 		$0 Hold
46
– – ﹤0.01% 2596
2020
Q2 		$0 Buy
+46
New +$646 ﹤0.01% 2634

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust's XBIT Position: Q4 2020 in Review

Glenmede Trust sold out of XBiotech (XBIT) in Q4 2020, closing a stake of 46 shares.

Glenmede Trust first reported a position in XBIT in Q2 2020 and held it in 2 quarters. The position peaked at $0 in Q3 2020. 66 funds tracked by Wall St. Rank hold XBIT as of Q4 2020.

  • Glenmede Trust reported no remaining XBiotech position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 46 XBiotech shares in Q4 2020.
  • Glenmede Trust first reported a position in XBiotech in Q2 2020 and held it in 2 quarters.
  • Glenmede Trust's XBiotech position peaked at $0 in Q3 2020.
  • 66 funds tracked by Wall St. Rank held XBiotech as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.